Anika Therapeutics Inc (ANIK):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(DATA904C5266)
◆英語タイトル:Anika Therapeutics Inc (ANIK) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C5266
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年9月
◆ページ数:51
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Anika Therapeutics Inc (ANIK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for tissue protection, repair and regeneration. It offers solutions for orthobiologics, dermal, ophthalmic, surgical and veterinary applications. Its major products include viscosupplementation and regenerative orthopedics products, advanced wound care devices, anti-adhesion gels, viscoelastic ophthalmic products, dental bone grafting adjuncts and joint dysfunction management fluids for horses. Its products are made from hyaluronic acid (HA) based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Anika has research and manufacturing facilities in Bedford, Massachusetts. The company offers its products through distributors in the Americas, Europe, the Middle East, and Asia. Anika is headquartered in Massachusetts, the US.

Anika Therapeutics Inc Key Recent Developments

Sep 05,2018: Anika appoints Dr. Cheryl Blanchard to its Board of Directors
Jul 25,2018: Anika reports second quarter 2018 financial results
May 02,2018: Anika Reports First Quarter 2018 Financial Results
Mar 05,2018: Anika Therapeutics Names Joseph Darling As CEO And Director
Feb 21,2018: Anika Announces Fourth Quarter and Full Year 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Anika Therapeutics Inc – Key Facts 6
Anika Therapeutics Inc – Key Employees 7
Anika Therapeutics Inc – Key Employee Biographies 8
Anika Therapeutics Inc – Major Products and Services 9
Anika Therapeutics Inc – History 11
Anika Therapeutics Inc – Company Statement 14
Anika Therapeutics Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 16
Company Overview 16
Anika Therapeutics Inc – Business Description 17
Business Segment: Dermal 17
Overview 17
Performance 17
Business Segment: Orthobiologics 17
Overview 17
Performance 17
Business Segment: Other 17
Overview 17
Business Segment: Others 18
Performance 18
Business Segment: Surgical 18
Overview 18
Performance 18
Geographical Segment: Europe 18
Target Markets 18
Performance 18
Geographical Segment: Other 18
Target Markets 18
Performance 18
Geographical Segment: US 19
Performance 19
R&D Overview 19
Anika Therapeutics Inc – Corporate Strategy 20
Anika Therapeutics Inc – SWOT Analysis 21
SWOT Analysis – Overview 21
Anika Therapeutics Inc – Strengths 21
Anika Therapeutics Inc – Weaknesses 22
Anika Therapeutics Inc – Opportunities 23
Anika Therapeutics Inc – Threats 24
Anika Therapeutics Inc – Key Competitors 25
Section 3 – Company Financial Ratios 26
Financial Ratios – Capital Market Ratios 26
Financial Ratios – Annual Ratios 27
Performance Chart 30
Financial Performance 30
Financial Ratios – Interim Ratios 31
Financial Ratios – Ratio Charts 32
Section 4 – Company’s Lifesciences Financial Deals and Alliances 33
Anika Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 33
Anika Therapeutics Inc, Medical Equipment, Deals By Type, 2012 to YTD 2018 34
Anika Therapeutics Inc, Recent Deals Summary 35
Section 5 – Company’s Recent Developments 36
Sep 05, 2018: Anika appoints Dr. Cheryl Blanchard to its Board of Directors 36
Jul 25, 2018: Anika reports second quarter 2018 financial results 37
May 02, 2018: Anika Reports First Quarter 2018 Financial Results 38
Mar 05, 2018: Anika Therapeutics Names Joseph Darling As CEO And Director 40
Feb 21, 2018: Anika Announces Fourth Quarter and Full Year 2017 Financial Results 41
Oct 25, 2017: Anika Reports Third Quarter 2017 Financial Results 42
Oct 23, 2017: Anika Announces the Forthcoming Appointment of Thomas M. Finnerty as Chief Human Resources Officer 43
Aug 28, 2017: Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs 44
Jul 27, 2017: Anika Announces Appointment of Joseph Darling as President 45
Jul 26, 2017: Anika Reports Strong Second Quarter 2017 Financial Results 46
Section 6 – Appendix 47
Methodology 47
Ratio Definitions 47
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Anika Therapeutics Inc, Key Facts 6
Anika Therapeutics Inc, Key Employees 7
Anika Therapeutics Inc, Key Employee Biographies 8
Anika Therapeutics Inc, Major Products and Services 9
Anika Therapeutics Inc, History 11
Anika Therapeutics Inc, Subsidiaries 15
Anika Therapeutics Inc, Key Competitors 25
Anika Therapeutics Inc, Ratios based on current share price 26
Anika Therapeutics Inc, Annual Ratios 27
Anika Therapeutics Inc, Annual Ratios (Cont...1) 28
Anika Therapeutics Inc, Annual Ratios (Cont...2) 29
Anika Therapeutics Inc, Interim Ratios 31
Anika Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 33
Anika Therapeutics Inc, Medical Equipment, Deals By Type, 2012 to YTD 2018 34
Anika Therapeutics Inc, Recent Deals Summary 35
Currency Codes 47
Capital Market Ratios 47
Equity Ratios 48
Profitability Ratios 48
Cost Ratios 49
Liquidity Ratios 49
Leverage Ratios 50
Efficiency Ratios 50

List of Figures
Anika Therapeutics Inc, Performance Chart (2013 - 2017) 30
Anika Therapeutics Inc, Ratio Charts 32
Anika Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 33
Anika Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 34

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Anika Therapeutics Inc (ANIK):企業の財務・戦略的SWOT分析(Anika Therapeutics Inc (ANIK) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆